Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
October 17, 2019 09:00 ET
|
Rafael Pharmaceutical Inc.
Cranbury, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
Rafael Selects aPriori for Product Cost Management
June 20, 2017 09:00 ET
|
aPriori Technologies
CONCORD, Mass., June 20, 2017 (GLOBE NEWSWIRE) -- aPriori, the leading provider of automated product cost management (PCM) software solutions, has been selected by Rafael Advanced Defense Systems, a...